V-Myb Mediates Cooperation of a Cell-specific Enhancer with the Mim-1 Promoter
Overview
Affiliations
The oncogenic transcription factor v-Myb disrupts myelomonocytic differentiation and transforms myelomonocytic cells by deregulating the expression of specific target genes. One of these genes, the chicken mim-1 gene, is activated by Myb exclusively in myelomonocytic cells and, therefore, has been an interesting model system to study how Myb activates a target in a lineage-specific manner. Previous work has suggested that Myb activates mim-1 by cooperating with CCAAT box/enhancer binding protein beta (C/EBPbeta) or other C/EBP transcription factors at the mim-1 promoter. We have now identified and characterized a powerful Myb-dependent enhancer located 2 kb upstream of the mim-1 promoter. The enhancer is preferentially active in myelomonocytic cells, confers Myb responsiveness onto a heterologous promoter, and dramatically increases Myb responsiveness of the mim-1 promoter. Chromatin immunoprecipitation demonstrates that v-Myb and C/EBPbeta are bound to the enhancer in v-Myb-transformed cells; furthermore, cooperation of the enhancer with the mim-1 promoter is greatly stimulated by C/EBPbeta and p300. Taken together, our results show that the regulation of mim-1 expression by v-Myb is more complex than previously assumed and involves two distinct regions of the mim-1 gene. A major function of v-Myb (in addition to its role at the mim-1 promoter) apparently is to activate the mim-1 enhancer and, together with C/EBPbeta and p300, facilitate its cooperation with the promoter. Interestingly, our work also shows that the v-Myb protein encoded by avian myeloblastosis virus is defective in this function, suggesting an explanation for why primary avian myeloblastosis virus-transformed myeloblasts do not express the mim-1 gene.
Kohler L, Reich S, Yusenko M, Klempnauer K, Begemann G, Schobert R Cancer Drug Resist. 2023; 6(1):59-77.
PMID: 37065868 PMC: 10099595. DOI: 10.20517/cdr.2022.90.
C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.
Klempnauer K Oncotarget. 2023; 14:174-177.
PMID: 36913305 PMC: 10010626. DOI: 10.18632/oncotarget.28377.
Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.
Schmidt T, Klempnauer K Molecules. 2022; 27(7).
PMID: 35408476 PMC: 9000602. DOI: 10.3390/molecules27072077.
Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner.
Biyanee A, Yusenko M, Klempnauer K Cells. 2022; 11(7).
PMID: 35406726 PMC: 8997952. DOI: 10.3390/cells11071162.
Yusenko M, Biyanee A, Frank D, Kohler L, Andersson M, Khandanpour C Cancers (Basel). 2022; 14(1).
PMID: 35008207 PMC: 8750090. DOI: 10.3390/cancers14010043.